Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease

A Ardizzoni; H Hansen; P Dombernowsky; T Gamucci; CD Kaplan; P Postmus; G Giaccone; G Schaefer; J Wanders; Jaap Verweij

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease

A Ardizzoni, H Hansen, P Dombernowsky, T Gamucci, CD Kaplan, P Postmus, G Giaccone, G Schaefer, J Wanders, Jaap Verweij

Research output: Contribution to journal › Article › Academic › peer-review

453 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2090-2096
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	15
Issue number	5
Publication status	Published - 1997

Research programs

EMC 04-01-DD-08-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ac8ec1a2acd843fca28328c66e4ac7e1,

title = "Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease",

author = "A Ardizzoni and H Hansen and P Dombernowsky and T Gamucci and CD Kaplan and P Postmus and G Giaccone and G Schaefer and J Wanders and Jaap Verweij",

year = "1997",

language = "Undefined/Unknown",

volume = "15",

pages = "2090--2096",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

TY - JOUR

T1 - Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease

AU - Ardizzoni, A

AU - Hansen, H

AU - Dombernowsky, P

AU - Gamucci, T

AU - Kaplan, CD

AU - Postmus, P

AU - Giaccone, G

AU - Schaefer, G

AU - Wanders, J

AU - Verweij, Jaap

PY - 1997

Y1 - 1997

M3 - Article

SN - 0732-183X

VL - 15

SP - 2090

EP - 2096

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -